Bio-Techne Corp TECH
72.61
0.04
0.06%
as of 25 Sep
- Market cap
- $11.4B
- P/E
- 62.1×
Follow TECH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
111.26 | 113.10 | 73.61 | 60.38 |
P/S ratio |
7.11 | 7.54 | 6.75 | 9.07 | |
P/FCF ratio |
38.60 | 41.09 | 30.30 | 41.86 | |
P/Operating CF |
313.52 | 111.21 | 94.27 | 115.48 | |
P/B ratio |
4.40 | 4.56 | 3.92 | 5.23 | |
Price to Tangible BV |
13.58 | 13.18 | 10.36 | 13.29 | |
EV/Sales |
7.25 | 7.62 | 6.75 | 9.03 | |
EV/EBITDA |
40.81 | 41.98 | 32.16 | 31.40 | |
EV/Operating CF |
35.09 | 37.16 | 27.71 | 37.55 | |
EV/FCF |
39.35 | 41.54 | 30.31 | 41.66 | |
Quick Ratio |
2.28 | 2.55 | 2.77 | 2.94 | |
Current Ratio |
4.22 | 4.54 | 4.49 | 4.55 | |
Net Debt/EBITDA |
2.15 | 1.10 | (0.10) | (0.66) | |
Debt/Assets |
11.88% | 10.31% | 7.84% | 7.73% | |
Debt/Equity |
0.15 | 0.13 | 0.10 | 0.09 | |
Asset Turnover |
0.46 | 0.47 | 0.47 | 0.47 | |
Operating CF/Net income |
0.72 | 2.17 | 1.70 | 1.75 | |
Capex/Depreciation |
(0.22) | (0.24) | (0.38) | (0.35) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.46% | 7.82% | 7.53% | 7.46% | |
Selling, General and Administrative Expense of Revenue |
40.56% | 38.43% | 35.11% | 35.24% | |
Intangible Assets out of Total Assets |
0.53 | 0.52 | 0.51 | 0.49 | |
Share Based Compensation of Revenue |
4.08% | 4.72% | 3.37% | 1.63% | |
Graham Net Nets |
0.01 | 0.01 | 0.03 | 0.02 | |
Graham Number |
11.93 | 12.29 | 14.60 | 18.86 | |
Earnings Yield |
0.90% | 0.88% | 1.36% | 1.66% | |
Free Cash Flow Yield |
2.59% | 2.43% | 3.30% | 2.39% | |
Revenue per Share |
1.84 | 1.90 | 1.99 | 2.06 | |
Operating CF per Share |
0.18 | 0.53 | 0.55 | 0.61 | |
Capex per Share |
(0.03) | (0.04) | (0.06) | (0.05) | |
Free Cash Flow per Share |
0.14 | 0.49 | 0.50 | 0.56 | |
Cash per Share |
0.93 | 1.11 | 1.34 | 1.70 | |
Shareholders Equity per Share |
12.64 | 12.90 | 13.34 | 13.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.64 | 12.90 | 13.34 | 13.52 | |
Free Cash Flow |
22.22 | 76.49 | 77.58 | 86.94 | |
Working Capital |
464.96 | 497.01 | 534.77 | 580.70 | |
Capital Expenditures |
(5.36) | (5.92) | (9.09) | (8.48) | |
Net Current Asset Value |
49.17 | 125.72 | 222.75 | 265.90 | |
EV/EBIT |
80.19 | 79.20 | 53.15 | 43.54 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.03 | |
Net Profit Margin |
13.33% | 12.85% | 16.39% | 17.01% | |
Price to Operating Income |
78.68 | 78.35 | 53.13 | 43.74 | |
| Other line items | |||||
Average Receivables |
203.79 | 201.28 | 225.85 | 211.73 | |
Average Payables |
30.86 | 29.69 | 27.57 | 26.01 | |
Average Inventory |
194.11 | 196.91 | 196.13 | 192.60 | |
Average Assets |
2,631.08 | 2,596.56 | 2,597.43 | 2,572.30 | |
Average Common Equity |
2,052.23 | 2,044.74 | 2,051.66 | 2,013.51 |
Columns are period end dates